Biotech & Life Sciences

A 40-year cold case in parasitology just cracked: York researchers found the molecular scissors that lets the sleeping sickness parasite stay invisible. The catch — it is not a drug target yet.

Sam Altman called it amazing. A dog with terminal cancer shrank her tumor by 75% after an AI-designed vaccine. But nobody, including UNSW, can explain why — and there is no publication to back it up.

Doctors drew a new line between risk factors and disease. The data says most people already crossed it — and the real fight is who pays for treatment.

ALTO-101 missed its primary endpoint in schizophrenia patients — but showed a signal in the sickest subgroup with no GI side effects. Alto is now looking for a buyer.

The same conference that validated evolocumab left olezarsen with a question mark. The difference is what the drugs actually do to the body — and the answer is shaping the future of preventive cardiology.

When radiologists did not know AI-generated X-rays were in the mix, they caught only 41% of them. Six years of training, coin-flip results. "AI has lowered the cost of fabricating medical truth to nearly nothing."

The FDA has granted breakthrough status to 99 AI medical devices. Not one generative AI device has been authorized. The gap tells you more about the program than the designations do.

The dream was simple: replace a daily pill with a weekly one. Two of the world’s largest drugmakers just learned the same lesson — HIV is harder to improve on than it looks.

The drug tariff is not the story. Who already bought their exemption is.

A universal cancer blood test built on microbial DNA promised to detect dozens of tumors from a single blood draw. It was retracted, Micronoma burned through $17.5M on the idea, and the rewrite is narrower: only colorectal cancer shows a reliable signal.

AI can already propose new discoveries. The harder problem: who runs the experiment to check if they are right?